A Practical Guide to the Diagnosis, Treatment, and Prevention of Neonatal Infections

Pediatric Clinics of North America

Volumn 62, Issue 2, 2015, Pages 491-508

  Santos, Roberto Parulan ^a   Tristram, Debra ^a  

^a ALBANY MEDICAL CENTER   (United States)

Author keywords

Antibacterial therapy; Antiviral therapy; Early onset sepsis; Late onset sepsis; Neonatal antimicrobial stewardship; Neonatal infections; Newborn sepsis; Respiratory viral infections in infants

Indexed keywords

ACICLOVIR; AMPHOTERICIN; AMPHOTERICIN B DEOXYCHOLATE; AMPICILLIN; C REACTIVE PROTEIN; CD64 ANTIGEN; CEFAZOLIN; CEFOTAXIME; CEFTRIAXONE; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; OSELTAMIVIR; PALIVIZUMAB; PENICILLIN DERIVATIVE; PREBIOTIC AGENT; PROBIOTIC AGENT; PROCALCITONIN; VALACICLOVIR; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; VALGANCICLOVIR;

ALGORITHM; ANTIBIOTIC PROPHYLAXIS; ANTISEPSIS; ANTIVIRAL THERAPY; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL MENINGITIS; BLOOD CELL COUNT; BLOOD CULTURE; CANDIDIASIS; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CHORIOAMNIONITIS; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; ESCHERICHIA COLI INFECTION; GROUP B STREPTOCOCCAL INFECTION; HAND WASHING; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INVASIVE ASPERGILLOSIS; LISTERIOSIS; MOLECULAR DIAGNOSIS; NECROTIZING ENTEROCOLITIS; NEWBORN CARE; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NEWBORN SCREENING; NEWBORN SEPSIS; NONHUMAN; OSTEOMYELITIS; PRACTICE GUIDELINE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; HYGIENE; MYCOSES; NEWBORN; SEPSIS; TRANSMISSION; VIRUS DISEASES;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; GANCICLOVIR; HUMANS; HYGIENE; INFANT, NEWBORN; MYCOSES; PREBIOTICS; PROBIOTICS; SEPSIS; VIRUS DISEASES;

EID: 84931051436     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2014.11.010     Document Type: Review

References (63)

1. Stoll B.J., Hansen N.I., Sanchez P.J., et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011, 127(5):817-826.
2. Camacho-Gonzalez A., Spearman P.W., Stoll B.J. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am 2013, 60(2):367-389.
3. Schelonka R.L., Maheshwari A. The many faces of B cells: from generation of antibodies to immune regulation. NeoReviews 2013, 14:e438-e447.
4. Kollmann T.R., Crabtree J., Rein-Weston A., et al. Neonatal innate TLR-mediated responses are distinct from those of adults. JImmunol 2009, 183(11):7150-7160.
5. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7(5):379-390.
6. Randolph D. The neonatal adaptive immune system. NeoReviews 2005, 6:e454-e462.
7. Polin R.A., Committee on Fetus and Newborn Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 2012, 129(5):1006-1015.
8. Tripathi N., Cotten C.M., Smith P.B. Antibiotic use and misuse in the neonatal intensive care unit. Clin Perinatol 2012, 39(1):61-68.
9. Cotten C.M., McDonald S., Stoll B., et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006, 118(2):717-722.
10. Cotten C.M., Taylor S., Stoll B., et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009, 123(1):58-66.
11. Kuppala V.S., Meinzen-Derr J., Morrow A.L., et al. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. JPediatr 2011, 159(5):720-725.
12. Cordero L., Ayers L.W. Duration of empiric antibiotics for suspected early-onset sepsis in extremely low birth weight infants. Infect Control Hosp Epidemiol 2003, 24(9):662-666.
13. Rhedin S., Lindstrand A., Rotzen-Ostlund M., et al. Clinical utility of PCR for common viruses in acute respiratory illness. Pediatrics 2014, 133(3):e538-e545.
14. Ronchi A., Michelow I.C., Chapin K.C., et al. Viral respiratory tract infections in the neonatal intensive care unit: the VIRIoN-I study. JPediatr 2014, 165(4):690-696.
15. Bennett N.J., Tabarani C.M., Bartholoma N.M., et al. Unrecognized viral respiratory tract infections in premature infants during their birth hospitalization: a prospective surveillance study in two neonatal intensive care units. JPediatr 2012, 161(5):814-818.
16. Steiner M., Strassl R., Straub J., et al. Nosocomial rhinovirus infection in preterm infants. Pediatr Infect Dis J 2012, 31(12):1302-1304.
17. Smith P.B., Benjamin D.K. Clinical approach to the infected neonate. Principles and practice of pediatric infectious diseases 2012, 536-538. Elsevier Saunders, Philadelphia. 4th edition. S.S. Long, L.K. Pickering, C.G. Prober (Eds.).
18. Santos R.P., Sanchez P.J., Mejias A., et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. Pediatr Infect Dis J 2007, 26(4):364-366.
19. Bizzarro M.J., Raskind C., Baltimore R.S., et al. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics 2005, 116(3):595-602.
20. Escobar G.J., Li D.K., Armstrong M.A., et al. Neonatal sepsis workups in infants>/=2000 grams at birth: a population-based study. Pediatrics 2000, 106(2 Pt 1):256-263.
21. Edwards M.S., Baker C.J. Bacterial infections in neonate. Principles and practice of pediatric infectious diseases 2012, 538-543. Elsevier Saunders, Philadelphia. 4th edition. S.S. Long, L. Pickering, C.G. Prober (Eds.).
22. Piantino J.H., Schreiber M.D., Alexander K., et al. Culture negative sepsis and systemic inflammatory response syndrome in neonates. NeoReviews 2013, 14:e294-e305.
23. Ottolini M.C., Lundgren K., Mirkinson L.J., et al. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatr Infect Dis J 2003, 22(5):430-434.
24. Effective biomarkers for diagnosis of neonatal sepsis. JPed Infect Dis 2014, 3(3):234-245.
25. Baron E.J., Miller J.M., Weinstein M.P., et al. Aguide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM)(a). Clin Infect Dis 2013, 57(4):e22-e121.
26. Mussap M. Laboratory medicine in neonatal sepsis and inflammation. JMatern Fetal Neonatal Med 2012, 25(Suppl 4):32-34.
27. Lartigue M.F., Kostrzewa M., Salloum M., et al. Rapid detection of "highly virulent" Group B Streptococcus ST-17 and emerging ST-1 clones by MALDI-TOF mass spectrometry. JMicrobiol Methods 2011, 86(2):262-265.
28. Mekouar H., Voortman G., Bernard P., et al. Capnocytophaga species and perinatal infections: case report and review of the literature. Acta Clin Belg 2012, 67(1):42-45.
29. Iatta R., Cafarchia C., Cuna T., et al. Bloodstream infections by Malassezia and Candida species in critical care patients. Med Mycol 2014, 52(3):264-269.
30. Schlebusch S., Price G.R., Hinds S., et al. First outbreak of PVL-positive nonmultiresistant MRSA in a neonatal ICU in Australia: comparison of MALDI-TOF and SNP-plus-binary gene typing. Eur J Clin Microbiol Infect Dis 2010, 29(10):1311-1314.
31. Pulcrano G., Roscetto E., Iula V.D., et al. MALDI-TOF mass spectrometry and microsatellite markers to evaluate Candida parapsilosis transmission in neonatal intensive care units. Eur J Clin Microbiol Infect Dis 2012, 31(11):2919-2928.
32. American Academy of Pediatrics Antimicrobial therapy for newborns. 2014 Nelson's pediatric antimicrobial therapy 2014, 17-36. American Academy of Pediatrics, Elk Grove Village (IL). J.S. Bradley (Ed.).
33. de Hoog M., Mouton J.W., van den Anker J.N. The use of aminoglycosides in newborn infants. Introduction to paediatric and perinatal drug therapy 2003, 117-140. Nottingham University Press, Notthingham (England). I. Choonara, A.J. Nun, G. Kearns (Eds.).
34. Begg E.J., Barclay M.L., Kirkpatrick C.J. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 1999, 47(1):23-30.
35. Novelli A., Mazzei T., Fallani S., et al. Invitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin. JChemother 1995, 7(4):355-362.
36. Craig W.A. Once-daily versus multiple-daily dosing of aminoglycosides. JChemother 1995, 7(Suppl 2):47-52.
37. Rotschafer J.C., Zabinski R.A., Walker K.J. Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 1992, 12(6 Pt 2):64S-70S.
38. Bryan C.S., John J.F., Pai M.S., et al. Gentamicin vs cefotaxime for therapy of neonatal sepsis. Relationship to drug resistance. Am J Dis Child 1985, 139(11):1086-1089.
39. Bradley J.S., Wassel R.T., Lee L., et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics 2009, 123(4):e609-e613.
40. Kimberlin D.W., Whitley R.J., Wan W., et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. NEngl J Med 2011, 365(14):1284-1292.
41. Kimberlin D.W., Baley J., Committee on Infectious Diseases, et al. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 2013, 131(2):e635-e646.
42. Kimberlin DW, Jester P, Sanchez PJ, etal. Six months versus six weeks of oral valganciclovir for infants with symptomatic congenital cytomegalovirus (CMV) disease with and without central nervous system (CNS) involvement: Results of a Phase III, randomized, double-blind, placebo-controlled, multinational study. 2013 ID Week. Infectious Disease Society of America. San Francisco (CA), October 5, 2013. Available at: Accessed October 7, 2014. https://idsa.confex.com/idsa/2013/webprogram/Paper43178.html.
43. Committee On Infectious Diseases Recommendations for prevention and control of influenza in children, 2014-2015. Pediatrics 2014, 134(5):e1503-e1519.
44. Bizzarro M.J., Ehrenkranz R.A., Gallagher P.G. Concurrent bloodstream infections in infants with necrotizing enterocolitis. JPediatr 2014, 164(1):61-66.
45. Segal I., Kang C., Albersheim S.G., et al. Surgical site infections in infants admitted to the neonatal intensive care unit. JPediatr Surg 2014, 49(3):381-384.
46. Verani J.R., McGee L., Schrag S.J., et al. Prevention of perinatal group B streptococcal disease-revised guidelines from CDC, 2010. MMWR Recomm Rep 2010, 59(RR-10):1-36.
47. Prevention CfDCa. Group B Strep (GBS). 2014. Available at: Accessed October 8, 2014. http://www.cdc.gov/groupBstrep/guidelines/index.html.
48. Polin R.A., Denson S., Brady M.T., et al. Strategies for prevention of health care-associated infections in the NICU. Pediatrics 2012, 129(4):e1085-e1093.
49. Boyce J.M., Pittet D., Healthcare Infection Control Practices Advisory Committee, et al. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002, 23(12 Suppl):S3-S40.
50. CDC. Hand Hygiene in Healthcare Settings. 2014. Available at: Accessed September 30, 2014. http://www.cdc.gov/handhygiene/.
51. Healy C.M., Pickering L.K. How to communicate with vaccine-hesitant parents. Pediatrics 2011, 127(Suppl 1):S127-S133.
52. American Academy of Pediatrics Hepatitis B. Red Book 2012, 369-390. American Academy of Pediatrics, Elk Grove Village (IL). L.K. Pickering (Ed.).
53. Committee on Infectious Diseases, American Academy of Pediatrics Recommended childhood and adolescent immunization schedule-United States, 2014. Pediatrics 2014, 133(2):357-363.
54. Lessin H.R., Edwards K.M., Committee On Practice And Ambulatory Medicine, et al. Immunizing parents and other close family contacts in the pediatric office setting. Pediatrics 2012, 129(1):e247-e253.
55. Sawyer M., Liang J.L., Messonnier N., et al. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Recomm Rep 2013, 62(7):131-135.
56. Healy C.M., Rench M.A., Baker C.J. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 2013, 56(4):539-544.
57. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014, 134(2):415-420.
58. Basu S. Neonatal sepsis: the gut connection. Eur J Clin Microbiol Infect Dis 2014, [Epub ahead of print].
59. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44(2):159-177.
60. Thomas D.W., Greer F.R., American Academy of Pediatrics Committee on Nutrition, et al. Probiotics and prebiotics in pediatrics. Pediatrics 2010, 126(6):1217-1231.
61. Alfaleh K., Anabrees J., Bassler D., et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011, (3). CD005496.
62. AlFaleh K., Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2014, (4). CD005496.
63. American Academy of Pediatrics Transmission-based precautions. Red ook: 2012 report of the committee on infectious diseases 2012, 164-167. American Academy of Pediatrics, Elk Grove Village (IL). 29th edition. L.K. Pickering, C.J. Baker, D.W. Kimberlin (Eds.).